HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica by Hildesheim, A et al.
The vast majority of cervical cancer cases are attributable to
human papillomavirus (HPV) infection (Bosch et al, 1995;
Schiffman et al, 1996; Nobbenhuis et al, 1999; Herrero et al,
2000). Our current challenge is to identify factors involved in the
rare progression of HPV infection, which is common and usually
benign, to cervical cancer and its immediate precursor, high-grade
squamous intraepithelial lesions (HSIL). 
Results from studies of HPV ‘co-factors’ suggest that reproduc-
tive factors, contraceptive use, cigarette smoking, and correlates of
sexual behaviour other than HPV infection might be associated
with HSIL and cervical cancer (henceforth referred to as
HSIL/CA) (Bosch et al, 1992; Munoz et al, 1993; Becker et al, 1994;
Moreno et al, 1995; Kjaer et al, 1996; Chaouki et al, 1998;
Chichareon et al, 1998; Ho et al, 1998; Kruger-Kjaer et al, 1998;
Olsen et al, 1998; Ngelangel et al, 1998; Roteli-Martins et al, 1998).
In most of these studies, HPV infection was accounted for through
statistical adjustment, i.e. by averaging the impact of other factors
in HPV-negative and HPV-positive cases and controls. Given
strong association between HPV and HSIL/CA (relative risks of ³
50), it is unclear whether effects observed for co-factors (relative
risks usually < 3) in these previous studies are real or due to
residual confounding by HPV. 
To address this concern, we conducted a prevalent case–control
study within a 10 077 woman population-based study in Guana-
caste, Costa Rica. We evaluated factors associated with progression
of HPV infection and its early cytologic manifestation (LSIL) by
comparing 146 HPV-positive cases of HSIL/CA against a group of
843 HPV-positive cohort members who did not have concurrent
HSIL/CA. We chose our control group to include only non-cases
(not diagnosed with HSIL) that were truly at risk of becoming a
case (infected with HPV). Although this study design likely atten-
uated the associations of cofactors that are associated with the
acquisition and possible persistence of infection, it avoided poten-
tial residual confounding by HPV. Thus, by including only HPV-
infected women in a strictly population-based study, we were
better able to estimate properly the role of possible HPV co-
factors. 
METHODS 
Cohort base 
A population-based cohort was established in Guanacaste, Costa
Rica in 1993/4 (Herrero et al, 1997, 2000). The study was
conducted after approval by the NCI and local institutional review
boards, and all participants provided informed consent. Cluster
sampling was utilized to select a representative sample of the adult
female population of Guanacaste (n = 10 738 eligible women). 
10 049 women (94% of eligibles) agreed to visit one of our 
study clinics. Because few women were expected to have 
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screen-detected invasive cancer, we supplemented our sample 
by including women from Guanacaste diagnosed with incident
cervical cancer in 1993/4. We attempted to recruit all cervical
cancer cases from major centres to which Guanacaste residents are
referred for diagnosis and treatment (Herrero et al, 1997). 28 of 31
additional cervical cancer cases identified in this manner were
alive and participated. The total number of women in our cohort
was therefore 10 077. 
Data and specimen collection 
Participants responded to a risk factor questionnaire that assessed
information on socio-demographic characteristics; sexual, repro-
ductive, and birth control practices; cigarette smoking; and sexually
transmitted diseases (STDs). Sexually active women underwent a
pelvic examination, at which time a Pap smear was prepared, cells
were collected for semi-automated ThinPrep cytology (Cytyc
Corp, Boxborough, MA), Cervigrams (National Testing
Laboratories, Fenton, MO) were taken, and cervical cells were
collected for HPV DNA testing (Herrero et al, 1997, 2000). 583
virgins, 291 women who refused to have a pelvic exam or for
whom physical problems prevented a pelvic, and 621 women who
reported having a hysterectomy were excluded. Thus, 8 582
women were considered for the present study (Figure 1). 
Women with cervical abnormalities by visual inspection,
cytology or cervicography, or who were in a 2% random sample of
the population were referred to colposcopy, at which time a second
questionnaire obtained medical history information and informa-
tion on douching practices. 
Lesions visible at colposcopy were biopsied. Based on review
of cytology, cervigram and histology, each woman was assigned a
diagnosis (Herrero et al, 1997; Schiffman et al, 1999). 40 women
(including supplemental cases) were diagnosed with cervical
cancer (39 histologically confirmed and one surgically evident),
128 with HSIL (93% histologically confirmed as having cervical
intraepithelial neoplasia 2 or 3 (CIN2/3); the remainder confirmed
by at least 2 reviewed cytologic diagnoses), and 189 with LSIL
(39% histologically confirmed as having cervical intraepithelial
neoplasia 1 or condylomatous atypia and the remainder confirmed
as LSIL by at least 2 screening tests). The remaining 8225 
participants had equivocal lesions (n = 661) or were cytologically
normal (n = 7564). 
HPV DNA testing 
Cervical cells were tested for HPV DNA using the Hybrid Capture
Tube test (Cox et al, 1995). This assay detects infection by 16
HPV types (6, 11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56,
58). Testing was performed for 8563 (99.8%) of the 8582 eligible
women with a pelvic examination. The PCR-based L1 consensus
primer HPV test was also performed on a set of 2974 women
(Hildesheim et al, 1994; Herrero et al, 2000). For the present study,
we utilized PCR data from 2300 women selected for PCR testing
due to 1) an abnormal screening test (1702), 2) HPV positivity by
Hybrid Capture (303), or 3) selection as a random sample of the
remaining cohort (295). PCR results from a group of women (n =
674) selected for testing on the basis of their sexual behaviour
were not utilized (except those that were selected as part of the
random sample of the remaining cohort) to avoid biasing our anal-
ysis of co-factors. PCR testing detected type-specific infection by
44 HPV types (2, 6, 11, 13, 16, 18, 26, 31, 32, 33, 34, 35, 39, 40,
42, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 66, 67, 68, 69,
70, 72, 73, 83, AE2, AE4, AE5, AE6, AE7, AE8, W13B, PAP155)
and infection with uncharacterized types (Herrero et al, 2000).
Using Hybrid Capture and PCR HPV testing results, women were
classified as 1) positive for high-risk HPV types (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68) if they tested positive for these
types by either method, 2) negative for high-risk HPV types but
positive for low-risk HPV types (all other HPV types and unchar-
acterized types) if they tested negative for high-risk types by both
Hybrid Capture and PCR (when available) and positive for low-
risk types by either method, or 3) HPV DNA-negative by Hybrid
Capture or both HPV DNA assays. By these criteria, 760 women
were positive for high-risk HPV types, 229 were positive for low-
risk types only, and 7574 were negative. Among positives, 596
(60.3%) were positive by Hybrid Capture and PCR, 24 (2.4%)
were positive by Hybrid Capture and had missing PCR data, 129
(13.0%) were positive by Hybrid Capture but negative by PCR,
and 240 (24.3%) were negative by Hybrid Capture but positive by
PCR, confirming the higher sensitivity of PCR. 
10 769 Eligible for Study (*)
10 077 Agreed to Participate
(93.6% Participation)
583 Virgins/No Pelvic
7574 HPV Negative 989 HPV Positive 19 Not tested for HPV
8582 Underwent Pelvic 291 Refused Pelvic 621 Hysterectomized
17 HSIL/CA 48 LSIL 146 HSIL/CA
116 HSIL 30 Cancers 140 LSIL 703 HPV Positive
843 LSIL/HPV 5 HSIL/CA 1 LSIL
*  Includes 10 738 women selected as part of our cohort and 31 supplemental invasive cancer cases (see text) 
Figure 1 Summary of study subject selection HPV co-factors for cervical neoplasia 1221
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Case–control study subjects 
Cases were HPV-positive women diagnosed with prevalent
HSIL/CA at entry into our cohort study (n = 146). These cases
comprised 86.9% (146/168) of all HSIL/CA cases in our cohort.
Of the 22 potential cases who were excluded, 17 (10.1%) tested
negative for HPV and 5 (3.0%) were not tested. HSIL/CA cases
were combined because HSIL is recognized as the immediate
precursor to cervical cancer. Although cancer cases were older
than HSIL cases (median age = 47 years vs 34 years, respectively),
comparison of HSIL (n = 116) and cancer (n = 30) cases control-
ling for age revealed no notable differences between the two
groups with respect to the many risk factors examined. 
HPV-positive women with and without a cytological diagnosis
of LSIL at entry into our cohort were included in a single control
group (n = 843) since LSIL is understood to be the cytological
manifestation of HPV infection (Schiffman and Brinton, 1995).
The 843 controls included 140 HPV DNA-positive women with
LSIL and 703 women with HPV DNA positivity only. Those with
LSIL comprised 74.1% (140/189) of all LSILs in our cohort. Of
the 49 potential controls who were excluded, 48 (25.4%) tested
negative for HPV and one (0.5%) was not tested. Women with
LSIL were slightly younger than those without (median age = 29
years for the LSIL vs 32 years for the HPV positive only group).
After control for age, the only notable differences observed
between controls with and without LSIL were a higher likelihood
of those with LSIL to test positive for high-risk HPV types (age-
adjusted RR = 2.0; 95% CI = 1.2–3.3) and a marginally greater
likelihood of these women to have had sexual intercourse >1/week
in the past year (age-adjusted RR = 1.5; 95% CI = 1.0–2.3). 
Statistical analysis 
The relative risk (RR), as estimated by the odds ratio, was the
measure of association between exposures and disease. 95% confi-
dence intervals (CI) determined the statistical significance of find-
ings. Logistic regression analysis permitted adjustment for age and
confounding co-factors (Breslow and Day, 1980). Dose–response
relationships were tested for statistical significance by treating
the categorical variable as continuous and evaluating whether the
resultant beta coefficient departed from zero. The fraction of
HSIL/CA among women infected with high-risk HPVs that is
attributable to exposure to co-factors was estimated by the method
of Benichou (Benichou, 2000). 
Analysis was conducted among all HPV-positive subjects and
also restricted to women positive for high-risk HPV types (136
cases and 624 controls). Both sets of results are presented in the
tables. HSIL cases comprise women with CIN2 and CIN3. To alle-
viate concerns that CIN2 cases might be false positive cases (i.e.
LSILs rather than HSILs) or that they may represent a different
biological entity, analyses were also repeated after exclusion of
CIN2 cases. While CIN2 cases were younger than CIN3/cancer
cases (median age = 31 and 38, respectively), results from the
analysis restricted to cases with CIN3 or cancer yielded similar
results (data not shown). The few differences noted in this
restricted analysis are presented in the text. Analyses adjusted for
age (18–24, 25–29, 30–44, 45–64, 65+), HPV type (high-risk vs
low-risk), number of pregnancies (0/1, 2/3, 4/5, 6+), and number
of cigarettes smoked per day (0, 1–5, 6+) are presented. Finer
adjustments for age did not significantly alter the estimates. Other
factors did not confound associations presented. 
Because controls were defined based on prevalent infection,
there was concern that risk estimates for cofactors of interest could
be biased by the overrepresentation in our control group of women
with either persistent viral infection or women with recently
acquired infections. We therefore conducted a parallel analysis
comparing cases to all cohort non-case members in our population-
based study, statistically adjusting for HPV. Results of this analysis
were identical to the results presented and therefore are not
shown. 
RESULTS 
HSIL/CA cases were, on average, 4 years older than controls 
(median age = 36 for HSIL/CA and 32 for LSIL/HPV). After
controlling for age, no association was seen between level of
education and risk of HSIL/CA (data not shown). The Pap smear
screening behaviour of cases and controls was very similar; 85.6%
of cases and 82.8% of controls reported ever having had a smear
and no association was observed between the interval since last
smear or the number of smears and HSIL/CA (age-adjusted RR for
5+ Paps compared to none = 1.1; 95% CI = 0.62–2.1). The age-
adjusted risk of HSIL/CA was 5.2 times higher (95% CI =
2.8–10.1) in women with high-risk HPV infection than those with
low-risk types. Only 10 HSIL/CA cases were positive for low-risk
HPV types alone, 5 of whom were positive for uncharacterized
types (Herrero et al, 2000). 
Age at first intercourse, interval between menarche and sexual
debut, and total number of sexual partners were not associated
with disease (Table 1). There was a suggestion that number of
sexual partners in the preceding year was negatively associated
with HSIL/CA (Ptrend = 0.14) and that an increased frequency of
sexual intercourse was associated with HSIL/CA (Ptrend = 0.15).
Women who reported ever being pregnant were at increased risk of
disease (RR = 4.5, 95% CI = 1.1–19), and among ever-pregnant
women risk increased with increasing number of pregnancies
(Ptrend = 0.10) and with live births (Ptrend = 0.04). Similar trends
were observed with the number of full-term (Ptrend = 0.06) and with
number of vaginal births (Ptrend = 0.05) (data not shown). Having
had one miscarriage/abortion (RR = 0.71, 95% CI = 0.42–1.2) or 2
or more miscarriages/abortions (RR = 0.60, 95% CI = 0.31–1.2)
was not significantly associated with risk of HSIL/CA. 
No significant associations were observed for age at first preg-
nancy for women who had their first pregnancy between the ages
20–24 (RR = 1.2, 95% CI = 0.76–1.2) and 25+ (RR = 0.77, 95%
CI = 0.37–1.6) compared to women who had their first pregnancy
when they were under 20 years of age. No significant association
was observed with any occurrence of stillbirths (RR = 0.53, 95%
CI = 0.23–1.2) or tubal/ectopic pregnancies (RR = 1.9, 95% CI =
0.37–10). No significant association were observed for women
who had one caesarean section (RR = 1.2; 95% CI = 0.61–2.4) or
2+ caesarean sections (RR = 0.70; 95% CI = 0.29–1.7). 
Overall, no significant association was observed between oral
contraceptive use and risk of HSIL/CA (Table 2). However, a
significant association between oral contraceptives and HSIL/CA
was evident among women with <3 pregnancies (Ptrend = 0.02;
Table 3), an effect that persisted after further adjustment for barrier
contraceptive use. Current use of barrier contraceptives (condoms
or diaphragms) was associated with a reduced risk of HSIL/CA;
further adjustment for oral contraceptive use did not affect the
pattern observed. Use of intrauterine devices and tubal ligations
were not related to risk (data not shown). There was a suggestion1222 A Hildesheim et al
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that use of injectable contraceptives (mainly Depo Provera) for ³1
year was associated with HSIL/CA (overall RR = 4.2; 95% CI =
0.96–19; RR in analysis restricted to high-risk HPV positives =
6.2; 95% CI = 1.1–34) in a small number of women (3 cases, 8
controls), consistent with previous findings (Herrero et al, 1990).
Current IUD users had a RR of 2.9 relative to non-users in analysis
restricted to cases with CIN3 or cancer (95% CI = 1.3–6.5). 
A> 2-fold association was observed between cigarette smoking
and HSIL/CA (Table 2) and risk increased with increasing number
of cigarettes smoked per day (Ptrend = 0.0007). No association was
observed between the smoking habits of the husbands/live-in part-
ners of our study participants and risk of HSIL/CA, in analysis
restricted to non-smoking women (data not shown). 
No significant associations with HSIL/CA were observed for
self-reported yeast infections, any of the sexually transmitted
diseases (STDs) other than HPV examined (gonorrhoea, syphilis,
HSV, other STDs), hand and foot warts, cold sores, other medical
conditions (tuberculosis, chicken pox, shingles, asthma), and
Table 1 Distribution and risk of HSIL/CA associated with sexual and reproductive practices 
Overall analysis
Analysis restricted to
women positive for
high risk HPV typesb
Variablea % Cases  % Controls  RRc 95% CI RRd 95% CI 
(n = 146) (n = 843)
Age at first intercourse 
<16 26.7 24.3 1.0 1.0
16–19 49.3 52.5 1.1 [0.69–1.7] 1.2 [0.72–1.9] 
20+ 24.0 23.2 1.2 [0.69–2.1] 1.2 [0.65–2.1] 
Years between menarche and sexual debut 
<2 14.4 14.6 1.0 1.0 
2–3 34.9 27.2 1.3 [0.72–2.3] 1.3 [0.69–2.3] 
4–5 25.3 25.2 1.3 [0.69–2.4] 1.3 [0.67–2.4] 
6+ 25.4 33.0 0.93 [0.50–1.7] 0.86 [0.45–1.6] 
Number of sexual partners in lifetime 
1 34.9 41.5 1.0 1.0 
2–3 43.2 41.7 1.2 [0.76–1.8] 1.2 [0.78–1.9] 
4+ 21.9 16.8 1.1 [0.67–1.9] 1.0 [0.59–1.8] 
Number of sexual partners in past year 
0 22.6 17.3 1.0 1.0 
1 76.0 77.9 0.87 [0.52–1.4] 0.89 [0.53–1.5] 
2+ 1.4 4.8 0.23 [0.05–1.1] 0.24 [0.05–1.1] 
Ptrend = 0.14 Ptrend = 0.16 
Frequency of sexual intercourse in past yeare
<1/week 21.2 27.0 1.0 1.0 
1/week 26.6 22.6 1.5 [0.83–2.8] 1.7 [0.91–3.2] 
>1 – ≤2/week 21.2 24.1 1.3 [0.67–2.5] 1.4 [0.70–2.7] 
>2–<4/week 20.4 17.7 1.6 [0.81–3.1] 1.3 [0.66–2.7] 
4+/week 10.6 8.6 1.8 [0.82–4.1] 2.1 [0.90–4.7] 
Ptrend = 0.15 Ptrend = 0.23 
Ever pregnant 
No 1.4 7.8 1.0 1.0 
Yes 98.6 92.2 4.5 [1.1–19] 4.6 [1.1–20] 
# Pregnancies 
1 9.7 19.4 1.0 1.0 
2 11.1 20.1 0.97 [0.44–2.1] 0.86 [0.38–1.9] 
3 16.7 14.9 1.7 [0.78–3.6] 1.4 [0.65–3.2] 
4–5 25.7 17.1 2.3 [1.1–4.8] 2.3 [1.1–4.9] 
6–8 22.9 13.1 2.7 [1.2–5.9] 2.5 [1.1–5.6] 
9+ 13.9 15.3 1.1 [0.47–2.7] 1.1 [0.43–2.6] 
Ptrend =0.10 Ptrend =0.12 
# Live birthsf
0–1 11.1 23.3 1.0 1.0
2 11.8 20.1 1.2 [0.56–2.5] 1.0 [0.48–2.2] 
3 18.7 16.7 1.7 [0.86–3.6] 1.5 [0.73–3.2] 
4–5 29.9 15.4 3.7 [1.8–7.4] 3.5 [1.7–7.2] 
6–8 16.0 12.9 2.2 [1.0–5.0] 2.2 [0.98–5.0] 
9+ 12.5 11.6 1.5 [0.61–3.5] 1.4 [0.56–3.4] 
Ptrend =0.04 Ptrend =0.04 
a1 control missing age at 1st intercourse information. 3 controls missing information on years between menarche and sexual debut. 1 control missing
information on number of partners in the past year. 1 control missing information on frequency of sexual intercourse in past year. bHigh-risk HPV types include
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68. cRR adjusted for age, HPV type, number of pregnancies, and number of cigarettes/day. dRR adjusted for
age, number of pregnancies, and number of cigarettes/day. eRestricted to those who reported being sexually active in past year. fLogistic models do not include
number of pregnancies. HPV co-factors for cervical neoplasia 1223
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douching practices (vinegar/water and other preparations) (data
not shown). 
We estimated the fraction of HSIL/CA that can be attributable to
exposures other than HPV among women who are infected with
high-risk HPV types. In those women with a high-risk HPV type
infection, 42% of HSIL/CA (95% CI = 21–63) can be attributed to
multiparity (having ³3 pregnancies), 10% to cigarette smoking
(95% CI = 3–18), and these 2 exposures together account for 44%
of HSIL/CA (95% CI = 23–66) (Table 4). 
DISCUSSION 
We observed that reproductive practices and smoking are important
risk factors for the development of HSIL/CA; in Guanacaste, among
women infected with high-risk HPV types, 44% of HSIL/CA can be
attributed to these 2 factors. We performed our analysis restricted to
only those women with HPV infection and chose controls from a
subset of women with HPV infection and without HSIL/CA i.e.,
LSIL, ASCUS or cytologically normal. We are the first to acknowl-
edge that this may not be an ideal control group. Ideally, one would
have wanted to select as controls women who had been infected
with HPV in the past (at the same time that the cases were infected)
but who resolved their infection (in contrast to the cases, whose
infection progressed). Given the lack of a reliable method for the
detection of past infection with one of many HPV types, selection of
such an ‘ideal’ control group was not possible. In selecting HPV-
infected women as controls, we likely biased our control group
towards women who have newly acquired HPV infections in which
there has been insufficient time for progression to HSIL/CA, or
women who have persistent (not transient) HPV infections. Women
who have newly acquired infections are more likely to have under-
gone a change in sexual behaviour that has led to infection. It is
unclear whether the inclusion of women with newly acquired infec-
tions would attenuate or exaggerate our risk estimates. Persistent
HPV infection, which occurs relatively infrequently, is an important
precursor to high-grade lesions. Inclusion of these women as
controls may therefore have attenuated our findings. This bias,
however, could not have explained our positive findings with
smoking and reproductive practices. Also reassuring is the fact that
in a parallel analysis in which all non-case cohort members were
included as controls and adjusting for HPV was achieved through
statistical means, identical results were obtained. This suggests that
the findings presented herein are robust. 
Table 2 Distribution and risk of HSIL/CA associated with birth control practices and cigarette smoking 
Overall analysis
Analysis restricted to
women positive for
high risk HPV typesb
Variablea % Cases  % Controls  RRc 95% CI RRd 95% CI 
(n = 146) (n = 843)
Oral contraceptive use 
Never 36.3  34.8  1.0  1.0 
Former use  34.9  40.4  0.90  [0.54–1.5]  0.93  [0.55–1.6] 
Current use  28.8  24.8  1.6  [0.89–2.9]  1.5  [0.83–2.8] 
<5 years of use  37.7  44.9  0.99  [0.59–1.7]  0.99  [0.58–1.7] 
5+ years of use  26.0  20.3  1.2  [0.71–2.2]  1.3  [0.70–2.3] 
Barrier contraceptive use 
Never 64.4  57.5  1.0  1.0 
Former use  31.5  32.1  1.0  [0.65–1.5]  0.91  [0.58–1.4] 
Current use  4.1  10.4  0.39  [0.16–.96]  0.39  [0.16–.97] 
<5 years of use  25.4  32.1  0.92  [0.57–1.5]  0.85  [0.52–1.4] 
5+ years of use  2.3  10.4  0.58  [0.17–2.1]  0.40  [0.09–1.8] 
Ptrend = 0.44  Ptrend = 0.22 
Cigarette smokinge
Never 79.5  90.3  1.0  1.0 
Former 8.2  3.7  2.4  [1.2–5.1]  1.7  [0.76–4.0] 
Current 12.3  6.0  2.3  [1.3–4.3]  2.3  [1.2–4.3] 
<10 years of use  8.2  4.9  2.6  [1.2–5.3]  2.2  [1.0–4.8] 
10 + years of use  12.3  4.8  2.2  [1.2–4.2]  2.0  [1.0–3.8] 
1–5 cigarettes/day  15.1  7.5  2.3  [1.3–3.9]  1.8  [.99–3.3] 
6+ cigarettes/day  5.4  2.2  2.7  [1.1–6.7]  3.1  [1.2–7.9] 
Ptrend = .0007  Ptrend = .003 
a1 control missing information on oral contraceptive use. 1 control was missing information on ever use and currency of use of barrier contraceptives. 16 cases
and 119 controls were missing information on duration of barrier contraceptives. bHigh-risk HPV types include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68. cRR adjusted for age, HPV type, number of pregnancies, and number of cigarettes/day. dRR adjusted for age, number of pregnancies, and number of
cigarettes/day. eRR adjusted for age, HPV types, and number of pregnancies. 
Table 3 RR estimates and 95% confidence intervals for the joint effect of
pregnancy and oral contraceptive usea
Oral contraceptive use  Number of pregnancies 
(# Cases # Controls)  (# Cases/# Controls) 
<3 pregnancies  3+Pregnancies 
(n = 32/372)  (n = 114/470) 
Never (53/293)  1.0  4.7 [1.8–12] 
<5 years (55/378)  1.8 [.65–4.9]  3.7 [1.5–9.3] 
5+years (38/171)  3.1 [1.1–9.1]  4.0 [1.5–10] 
RRs adjusted for age, HPV type, and number of cigarettes/day. aEstimates
presented are from analysis including all subjects. Similar estimates were
obtained in analysis restricted to high-risk HPV positive women. 1224 A Hildesheim et al
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The major strengths of our study are its population-based design
and high participation rate (>93%), and its ability to adequately
account for confounding by HPV, a known causative agent in the
pathogenesis of HSIL/CA. A further strength of the present study
was our ability to examine associations restricted to HPV types
linked with HSIL/CA, providing further assurance that observa-
tions are not confounded by HPV type. Estimates from our anal-
ysis restricted to HPV-infected women were identical to those in
the population-based analysis, suggesting that HPV was not a
significant confounder of the observed associations with high-
grade lesions. Our findings substantiate earlier reports that
smoking (Reeves et al, 1987; Bosch et al, 1992; Munoz et al, 1993;
Ho et al, 1998; Olsen et al, 1998; Roteli-Martins et al, 1998) and
parity (Brinton et al, 1980; Bosch et al, 1992; Munoz et al, 1993;
Schiffman et al, 1993) were associated with cervical cancer.
Finally, since the Pap smear screening behaviour of cases and
controls were similar in our rural population, the observed effects
cannot be explained by differential detection due to differences in
Pap smear screening. 
Among HPV-infected women, no residual effect of lifetime
number of sexual partners was observed. This finding, along with
the lack of disease association observed for self-reported STDs
other than HPV, suggests that STDs other than HPV are unlikely to
be important in the progression of HPV to HSIL/CA. Self-
reporting of STDs in this population was lower than the expected
prevalence for these infections suggesting that there was signifi-
cant underreporting. To better address the role of non-HPV STDs
and lower reproductive tract alterations as risk factors for infected
women to progress to high-grade lesions, future studies will use
biological assays, such as DNA and serological assays, to ascer-
tain exposure to other STDs, bacterial vaginosis and cervical
inflammation. Thus, the unreliability of self-reported STDs will be
avoided. The tendency for women with multiple recent partners to
be at a non-significantly reduced risk of HSIL/CA is consistent
with the natural history of cervical neoplasia, where detectable
infections and LSILs occur proximal to exposure (i.e. recent
sexual behaviour is closely linked to HPV infection and LSIL)
while HSILs do not develop until several years after initial
exposure. 
The underlying mechanism for the observed association between
pregnancies and HSIL/CA is unknown. Our finding that still-births
did not increase risk and that caesarean sections did not reduce risk
argues against the possibility that trauma during delivery explains
the observed associations. Other possible explanations include
influences of endogenous hormones, nutrition and modulation of
the immune response to HPV by pregnancy (Fife et al, 1987;
Schneider et al, 1987; Pater et al, 1988; Mitrani-Rosenbaum et al,
1989; Rando et al, 1989; Smith et al, 1991; Mittal et al, 1993;
Arbeit et al, 1996; Bartholomew et al, 1998; Fife et al, 1999).
Multiparity was not associated with number of lifetime or recent
sexual partners and thus the association with HSIL/CA was not
confounded by these sexual parameters. 
Various mechanisms might explain the association between
smoking and HSIL/CA. Constituents of cigarettes, including carci-
nogens, have been found in the cervical mucus of female smokers
(Prokopczyk et al, 1997). In addition, exposure to tobacco may
have a detrimental effect on the ability of the host to mount an
effective immune response against viral infections (Johnson et al,
1990; Geng et al, 1996). It is important to point out that the preva-
lence of smoking among women in our study was low and that
among smokers, intensity of use was moderate. In populations
where prevalence and intensity of smoking are higher, the effect of
smoking on risk of HSIL/CA might be even more dramatic. 
Results of studies examining the association between oral
contraceptives and HSIL/CA have been conflicting (Bosch et al,
1992; Munoz et al, 1993; Becker et al, 1994; Moreno et al, 1995;
Kjaer et al, 1996; Chaouki et al, 1998; Chichareon et al, 1998; Ho
et al, 1998; Kruger-Kjaer et al, 1998; Ngelangel et al, 1998;
Roteli-Martins et al, 1998). We failed to observe an effect of oral
contraceptives overall, but noted a significant association between
oral contraceptive use and HSIL/CA among women with <3 preg-
nancies, an effect also observed with other subdivisions of preg-
nancy numbers (e.g., <2 pregnancies and <4 pregnancies). While
one must be cautious when interpreting results from this subgroup
analysis, it is possible that multiparous women who use oral
contraceptives are non-compliant or that misclassification of dura-
tion of use is higher among multiparous women who start and stop
use on multiple occasions. If so, the true effect of oral contracep-
tives on disease risk might be larger than that observed in our
study. 
It has been postulated that early initiation of sexual activity is a
risk factor for HSIL/CA because of metaplasia resultant from
ectopy at young ages (Harris et al, 1980). The lack of association
between age at first intercourse, age at first pregnancy, or years
between menarche and sexual debut and HSIL/CA in our study
argues against this ‘vulnerability period’ theory. 
It is unclear why barrier contraception (condoms and/or dia-
phragms) was associated with reduced risk of HSIL/CA among
already HPV-infected women. It is possible that barrier users vary
from nonusers with regards to unmeasured lifestyle factors asso-
ciated with disease progression, or that barrier contraceptive use
modulates the degree of exposure to HPV. The protective effect
observed among barrier contraceptive users might also reflect a
protection afforded by barrier contraceptives against STDs other
than HPV. It should be noted, however, that no effect of self-
reported STDs on risk of HSIL/CA was observed in our study, 
as discussed above. Replication of this unexpected finding is
required before it is accepted. 
Table 4 Proportion of HSIL and cervical cancer cases attributable to multiparity and cigarette smoking, among women
exposed to high-risk HPV 
Exposure %  Exposed  RRa Attributable fraction (95% CI) 
>3 pregnancies  54.7%  2.2  42% (21–63) 
Cigarette smoking  10.4%  2.1  10% (3–18) 
³ 3 pregnancies and/or cigarette smoking  59.3%  2.2  44% (23–66) 
aRRs adjusted for age. Pregnancy RR additionally adjusted for number of cigarettes/day. Cigarette smoking RR
additionally adjusted for number of pregnancies. HPV co-factors for cervical neoplasia 1225
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We included as controls HPV-infected women with and without
cytological evidence of LSIL. This was done because previous
work has shown that LSIL is the cytological manifestation of HPV
infection (Schiffman and Brinton, 1995). The fact that HPV-
infected women with and without LSIL were similar with respect
to most factors examined further justifies combining them into a
single group. However, a few differences noted between these 2
groups warrant mention. First, compared to HPV-positive women
with no evidence of LSIL, those diagnosed with LSIL were twice
as likely to be infected with high-risk HPV types, as noted by us in
a previous publication (Herrero et al, 2000). Second, HPV-positive
women with LSIL were younger than those without LSIL
suggesting that in older women HPV infections are less likely to
manifest themselves cytologically. 
Our study is cross-sectional; replication of our findings in pros-
pectively followed women is needed. Follow-up of women in our
Costa Rican cohort should permit such an analysis once sufficient
follow-up time is accumulated. In the prospective study, we can
use more appropriate controls, women who get an HPV infection
at the same time as cases but instead of progressing to high-grade
lesions, they resolved their infection. Another limitation of our
study is the availability of sensitive PCR-based HPV testing for
only a subset of participants. Some cytologically normal women
with low-level HPV infections could have been missed by our
testing strategy. If women with low-level infections differ from
those with higher level infections with respect to the risk factors
we examined, our risk estimates could be biased. This bias,
however, would likely have attenuated differences between our
cases and controls and should not explain away any of our find-
ings. Our study had limited power to evaluate CIN2 cases separ-
ately from CIN3/cancer cases. However, our findings are robust
since exclusion of CIN2 cases did not alter results. Another limita-
tion is the relatively small number of cancer cases, which
precluded analyses to distinguish factors associated with HSIL
from those associated with the transition from HSIL to invasive
cancer. Since HSIL is the immediate precursor of cervical cancer
and since the absolute risk of HSIL progression without treatment
is high, factors linked to HSIL are also likely to be linked to inva-
sive cancer. In fact, excluding the cancer cases and restricting our
analysis to HSIL alone did not alter our risk estimates. However, it
is likely that our study would have missed factors uniquely asso-
ciated with the progression of HSIL to cervical cancer. 
In summary, we observed in our population-based study
restricted to HPV positive women that reproductive practices and
cigarette smoking are important co-factors for the development
of HSIL/CA. Barrier contraceptive use may reduce the risk of
HSIL/CA while OC use may be associated with an increased risk
of disease in a subgroup of women. 
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